Genetic studies have informed on biological pathways modulating lipid and lipoprotein metabolism, which have been exploited to design new drugs Inhibition of PCSK9 expression by long-acting siRNA is effective in lowering LDL-C Bi-annual administration of long-acting siRNA will improve adherence and represents a novel therapeutic strategy in high and very high CV risk patients Selective PPARa modulator (SPPARM) pemafibrate might represent a new option for combination LLT to decrease the risk of macro and microvascular complications in diabetes. Targeting ANGPTL3 is showing highly effective in reducing LDL-C and total triglycerides Targeting ApoCIII reduces TGRL by an LPL-independent mechanism
New and Emerging Therapies for Dyslipidemia
Zambon A.
Writing – Original Draft Preparation
;
2022
Abstract
Genetic studies have informed on biological pathways modulating lipid and lipoprotein metabolism, which have been exploited to design new drugs Inhibition of PCSK9 expression by long-acting siRNA is effective in lowering LDL-C Bi-annual administration of long-acting siRNA will improve adherence and represents a novel therapeutic strategy in high and very high CV risk patients Selective PPARa modulator (SPPARM) pemafibrate might represent a new option for combination LLT to decrease the risk of macro and microvascular complications in diabetes. Targeting ANGPTL3 is showing highly effective in reducing LDL-C and total triglycerides Targeting ApoCIII reduces TGRL by an LPL-independent mechanism| File | Dimensione | Formato | |
|---|---|---|---|
|
New Therapies, Endocrine Clinics 2022.pdf
non disponibili
Tipologia:
Published (publisher's version)
Licenza:
Accesso privato - non pubblico
Dimensione
1.17 MB
Formato
Adobe PDF
|
1.17 MB | Adobe PDF | Visualizza/Apri Richiedi una copia |
Pubblicazioni consigliate
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
